Project Grant R21AI176237
- Shy Therapeutics, LLC received a $300,616 Project Grant award from the National Institute of Allergy and Infectious Diseases (NIAID) under the Allergy and Infectious Diseases Research program (CFDA 93.855) effective September 1, 2025, through August 31, 2027. The award supports the development of a novel class of antifungal small-molecule therapeutics designed to address the growing public health threat of drug-resistant fungal infections. The project will deliver research products including...
- Federal Project Grant Award Summary Life Pharms Inc. received a $300,000 Project Grant award from the National Institute of Allergy and Infectious Diseases (NIAID) under the Allergy and Infectious Diseases Research program (CFDA 93.855), effective September 19, 2025, with completion targeted for August 31, 2027. The award supports the development of LP10581, a novel small-molecular-weight antifungal compound designed to address the critical public health challenge of drug-resistant fungal...
- Federal Project Grant Award Summary Texas A&M University System Health Science Center received a $192,500 Project Grant from the National Institute of Allergy and Infectious Diseases (NIAID) under the Allergy and Infectious Diseases Research program (CFDA 93.855), awarded on June 1, 2026, with completion scheduled for May 31, 2028. The award supports a two-year research initiative focused on developing novel antifungal therapeutics to combat multi-drug-resistant fungal infections,...
- Federal Project Grant Award Summary Halomine Inc. (doing business as Avantguard) received a $299,435 Project Grant from the National Institute of Allergy and Infectious Diseases (NIAID) under the Allergy and Infectious Diseases Research program (CFDA 93.855) to develop and optimize a novel, bio-inspired chloramine-based antifungal treatment for cutaneous fungal infections. The award, effective August 1, 2025 through July 31, 2026, supports the advancement of a stabilized chloramine polymer...
- Federal Grant Award Summary Prokaryotics Incorporated received a $299,697 Project Grant from the National Institute of Allergy and Infectious Diseases (NIAID) under the Allergy and Infectious Diseases Research program (CFDA 93.855), awarded September 19, 2025, with a completion date of August 31, 2026. The award supports the development of a mechanistically novel antifungal agent targeting fks1 and cell wall 1-3-D-glucan biosynthesis to address life-threatening fungal infections in hospital...
- Federal Project Grant Award Summary Microbiotix, Inc. received a Project Grant award of $299,946 from the National Institute of Allergy and Infectious Diseases (NIAID) under the Allergy and Infectious Diseases Research program (CFDA 93.855), effective September 22, 2025, with completion targeted for August 31, 2027. The award supports the development of novel benzyl-piperidine (BP) antifungal agents to treat intractable mucormycosis infections caused by Mucorales fungi, a WHO high-priority...
- This $298,045 Project Grant award from the National Institutes of Health's National Center for Advancing Translational Sciences (CFDA 93.350) aims to establish and develop a high-throughput screening (HTS) assay to identify novel bacterial DNA gyrase poisoning inhibitors. The key products and services to be delivered under this one-year award include: Developing a unique HTS assay to rapidly discover bacterial DNA gyrase poisoning inhibitors from small molecule libraries. This assay will...
- Federal Grant Award Summary The National Institute of Allergy and Infectious Diseases (NIAID) awarded the University of Massachusetts Medical School a $840,687 Project Grant under the Allergy and Infectious Diseases Research program (CFDA 93.855) effective August 15, 2025, with completion targeted for July 31, 2030. The research initiative investigates the molecular mechanisms by which Bruton's Tyrosine Kinase (BTK) inhibitors—FDA-approved cancer therapeutics—increase susceptibility to...
- Federal Grant Award Summary Clemson University's Division of Research received a $418,378 Project Grant award from the National Institute of Allergy and Infectious Diseases (NIAID) under the Allergy and Infectious Diseases Research program (CFDA 93.855), effective April 1, 2026 through March 31, 2031. The award supports investigator-initiated biomedical research to advance understanding of fungal drug resistance mechanisms in Aspergillus fumigatus, a pathogenic mold responsible for invasive...
- Federal Project Grant Award Summary Tufts Medical Center Parent, Inc. (Tufts Medical Center) received a $190,768 Project Grant award from the National Institute of Allergy and Infectious Diseases (NIAID) under the Allergy and Infectious Diseases Research program (CFDA 93.855), effective September 2, 2025, through August 31, 2028. The award funds development of a rapid transcriptomic assay for antimicrobial susceptibility testing (AST) of Mycobacterium abscessus, a nontuberculous mycobacterium...
HTS WITH ASPERGILLUS FUMIGATUS FOR NOVEL, MOLD-ACTIVE ANTIFUNGALS - PROJECT SUMMARY MOLDS CAUSE DEVASTATING INFECTIONS IN DIVERSE PATIENT POPULATIONS WORLDWIDE. THE MOST LIFE-THREATENING OF THESE DISEASES ARE INVASIVE MOLD INFECTIONS (IMIS) WHICH PRIMARILY AFFECT IMMUNE COMPROMISED INDIVIDUALS INCLUDING THOSE UNDERGOING CHEMOTHERAPY, LONG TERM STEROID TREATMENT, AND HEMOPOIETIC OR SOLID ORGAN TRANSPLANT PATIENTS. IMIS CAN BE CAUSED BY A HANDFUL OF ENVIRONMENTAL MOLDS BUT THE MOST COMMON SPECIES IS ASPERGILLUS FUMIGATUS. CURRENTLY, THERE ARE THREE CLASSES OF ANTIFUNGALS USED TO TREAT IMIS; HOWEVER, DESPITE AVAILABLE TREATMENTS, MORTALITY RATES REMAIN UNACCEPTABLY HIGH, TYPICALLY ~50% BUT REACHING 80-100% FOR SOME MOLD SPECIES AND PATIENT COHORTS. ONE CONTRIBUTING FACTOR TO THE HIGH MORTALITY RATES IS INTRINSIC RESISTANCE OF SOME MOLD SPECIES TO SOME OR ALL CLINICAL ANTIFUNGALS. IN ADDITION, ACQUIRED ANTIFUNGAL RESISTANCE, PARTICULARLY AMONG A. FUMIGATUS ISOLATES, IS BECOMING A CLINICAL PROBLEM WORLDWIDE. IN THE DRUG DEVELOPMENT SPACE, ANTIFUNGAL DRUG SCREENS OFTEN FOCUS ON YEAST SPECIES. THIS IS DUE IN PART TO THE TECHNICAL EASE OF HANDLING THESE ORGANISMS IN HIGH-THROUGHPUT SETTINGS. YEAST GROWTH IS TIGHTLY CORRELATED TO OPTICAL DENSITY, FACILITATING LARGE-FORMAT GROWTH-BASED SCREENS. IN CONTRAST, MOLDS GROW AS FILAMENTS WHICH CREATE A HETEROGENOUS CULTURE OF TANGLED CELLS WHOSE OPTICAL DENSITY IS NOT WELL CORRELATED TO BIOMASS. ADDITIONALLY, THE INABILITY TO HANDLE THESE CULTURES WITH AUTOMATED LIQUID HANDLING DEVICES CREATES ADDITIONAL CHALLENGES IN HIGH THROUGHPUT SETTINGS. HOWEVER, THE HIGH MORTALITY RATES AND LIMITED ACTIVITY OF CLINICAL ANTIFUNGAL AGAINST MOLDS WARRANTS MORE FOCUS ON THESE ORGANISMS IN ANTIFUNGAL DRUG SCREENING. TO ADDRESS THE NEED FOR MOLD-ACTIVE ANTIFUNGALS, WE DEVELOPED AND VALIDATED A HIGH-THROUGHPUT COMPATIBLE SCREENING ASSAY TO SCREEN DIRECTLY WITH A. FUMIGATUS. THIS LUCIFERASE-BASED ASSAY MEASURES THE RELEASE OF THE CYTOSOLIC ENZYME, ADENYLATE KINASE (AK), AS A READOUT FOR FUNGAL CELL LYSIS. UNIQUELY, WHEN USED WITH A. FUMIGATUS THIS ASSAY CAN ALSO DETECT COMPOUNDS THAT INHIBIT GERMINATION THROUGH THE SUPPRESSION OF BACKGROUND AK RELEASE THAT OCCURS DURING NORMAL GERMINATION AND VEGETATIVE GROWTH. HERE, WE PROPOSE A HIGH- THROUGHPUT SCREEN OF A LARGE LIBRARY OF SYNTHETIC, DRUG-LIKE MOLECULES FOR NOVEL SCAFFOLDS WITH ANTI-MOLD ACTIVITY USING OUR AK SCREENING PLATFORM. PILOT LARGE-FORMAT SCREENS HAVE ALREADY IDENTIFIED CANDIDATE MOLECULES FOR FURTHER DEVELOPMENT; THUS, BASED ON THE SCALE AND DIVERSITY OF OUR PROPOSED SCREEN, WE EXPECT TO IDENTIFY ADDITIONAL MOLD-ACTIVE ANTIFUNGALS WITH NOVEL MECHANISMS OF ACTION FOR PRECLINICAL DEVELOPMENT.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | $194.4k | 5/5/25 | ||
| Not listed | $23.3k | 9/11/24 | ||
| Not listed | $23.3k | 9/11/24 | ||
| Not listed | $209.9k | 6/12/24 | ||
| Not listed | $209.9k | 6/12/24 |